Related Experiment Video
Updated: Aug 29, 2025
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
Published on: February 24, 2023
Current and promising treatment strategies in glioma
Paulina Śledzińska1, Marek Bebyn1, Jacek Furtak2,3
1Molecular Oncology and Genetics Department, Innovative Medical Forum, The F. Lukaszczyk Oncology Center, 85-796 Bydgoszcz, Poland.
Abstract:
Gliomas are the most common primary central nervous system tumors; despite recent advances in diagnosis and treatment, glioma patients generally have a poor prognosis. Hence there is a clear need for improved therapeutic options. In recent years, significant effort has been made to investigate immunotherapy and precision oncology approaches. The review covers well-established strategies such as surgery, temozolomide, PCV, and mTOR inhibitors. Furthermore, it summarizes promising therapies: tumor treating fields, immune therapies, tyrosine kinases inhibitors, IDH(Isocitrate dehydrogenase)-targeted approaches, and others. While there are many promising treatment strategies, none fundamentally changed the management of glioma patients. However, we are still awaiting the outcome of ongoing trials, which have the potential to revolutionize the treatment of glioma.
Insights
Glioma treatment needs improvement, with ongoing trials exploring novel therapies like immunotherapy and precision oncology. While current options exist, future treatments may revolutionize patient outcomes.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
Background:
- Gliomas are primary central nervous system tumors with poor patient prognosis.
- Current diagnostic and therapeutic advancements offer limited improvement.
Purpose of the Study:
- To review established and emerging therapeutic strategies for glioma.
- To highlight the need for novel treatment approaches.
Main Methods:
- Literature review of established treatments (surgery, temozolomide, PCV, mTOR inhibitors).
- Summary of promising therapies including tumor treating fields, immunotherapy, tyrosine kinase inhibitors, and Isocitrate dehydrogenase (IDH)-targeted approaches.
Main Results:
- Established treatments offer limited impact on glioma prognosis.
- Numerous promising therapies are under investigation.
Conclusions:
- Despite ongoing research, no single therapy has fundamentally altered glioma patient management.
- Future clinical trials hold potential for revolutionary treatment advancements.
